BioSig Technologies, Inc. Invited to Present at the Investing for Cures Conference in New York City
Company Founder, Kenneth L. Londoner to Present the Company's PURE EP Platform
MINNEAPOLIS, MN -- (Marketwired) -- 10/27/15 -- BioSig Technologies, Inc. (OTCQB: BSGM) today announced that it has been selected to present at the Investing for Cures 2015 to be held on Wednesday, November 4, 2015 at the Union League in New York City.
IFC 2015 will bring together major leaders in the intersecting worlds of philanthropies, foundations, Family Offices, high net worth investors, charitable trusts and prominent life sciences companies to explore the latest innovative technologies and therapeutic efforts that will transform healthcare.
Investing for Cures began five years ago to forge a coalition between medical experts, 'best of breed' innovative life sciences companies, and investors in order to create an ongoing dialog between the best industry talent and investors, and to propel leading efforts into sustainable clinical outcomes and successful return on investment.
Twenty companies will present to one hundred investors of the highest caliber. Each company undergoes a highly selective screening process; those that are chosen are scheduled to present. This screening process ensures that high quality presenters match the demand and qualifications of the investors in attendance.
William Podd, founder and CEO of Landmark Venture Forums who created Investing for Cures 2015 commented, "We are pleased to welcome BioSig Technologies to present at our annual signature event. We created Investing for Cures to explore innovative technologies that will transform the state of healthcare and thereby benefit society. BioSig was selected based upon exhibition of these characteristics."
Kenneth L. Londoner, Executive Chairman and Founder of BioSig stated, "We are thankful to have been selected to present at IFC 2015. We are looking forward to sharing our PURE EP story and our company's commitment to making a real difference in the lives of patients suffering with Atrial Fibrillation and Ventricular Tachycardia. The IFC 2015 format allows the Company access to very high quality, long term investors that also share a passion for making a difference by bringing real clinical solutions to the global marketplace."
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace(1) (http://www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed preclinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Investor Relations
Brian McLaughlin
BioSig Technologies, Inc.
bmclaughlin@biosigtech.com
917-370-9817
Source: BioSig Technologies, Inc.
Released October 27, 2015
